Moreover, we evaluated the clinical value of FAP for predicting the immunotherapeutic outcomes in a cohort of patients with advanced NSCLC who received PD-1 blockade therapy, which yielded a more complete understanding of interactions between FAP and T cell infiltration and uncovered their roles in the immunotherapeutic response. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.